24.54MMarket Cap-675P/E (TTM)
2.500High2.331Low62.76KVolume2.390Open2.320Pre Close153.72KTurnover1.31%Turnover RatioLossP/E (Static)9.89MShares11.30052wk High0.34P/B11.88MFloat Cap2.08052wk Low--Dividend TTM4.79MShs Float200.000Historical High--Div YieldTTM7.29%Amplitude2.080Historical Low2.449Avg Price1Lot Size
HOOKIPA Pharma Stock Forum
With Gilead Science holding 15% share, it is worthwhile to hold long...
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma (NASDAQ: HOOK) announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented at SITC 2024. The presentation will be delivered as a late-breaking poster by Dr. Alan Ho, Chief of Head and Neck Oncology Service at Memorial Sloan Cancer Cent...
HOOKIPA Pharma Doses First Patients With Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
16 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related...
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split - July 10,2024
Ladies and gentleman, On the 17 June 2024, 5 directors and 1 chairperson have collectively bought over 340K of shares at around 0.71 $.
Just wanted to share .... 😊
No comment yet